Federal Guidance

NIH Guidance documents on DSMPs/DSMB

The NIH requires a DSMB for Phase III clinical investigations (or any multi-site clinical trial) involving interventions that entail potential risk to participants. For Phase I and II trials, a DSMB may be appropriate if the studies have multiple clinical sites, are blinded or employ particularly high-risk interventions or vulnerable populations.

NIH Institute Specific Data and Safety Monitoring Guidance

 

 

Last modified: Dec 14, 2012
ID=x10296